RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This 24-week study will compare the safety and effectiveness of medication treatment alone (risperidone or aripiprazole) to medication treatment in combination with a parent management training program.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: Risperidone

Criteria

Inclusion Criteria:

• Autistic Disorder, Asperger's Disorder, or Pervasive Developmental Disorder not otherwise specified

• Weight > 30 lbs

• IQ >= 35 or mental age of at least 18 months

Exclusion Criteria:

• Psychotic Disorder

• History of intolerance or nonresponse to risperidone

• Pregnancy

• History of neuroleptic malignant syndrome